It is very uncertain whether continuous Infusion changes minor adverse events compared with pulse spray technique (very low certainty).
It is very uncertain whether pharmacomechanical thrombolysis (Cragg® catheter) changes minor adverse events compared with pulse spray technique (very low certainty).
It is very uncertain whether pharmacomechanical thrombolysis (Cragg® catheter) changes major adverse events compared with pulse spray technique (very low certainty).
It is very uncertain whether surgical thrombectomy changes major adverse events compared with pulse spray technique (very low certainty).
The review found no eligible studies for this question.
Monthly pegloticase showed no clear difference in total adverse events compared with placebo (moderate certainty).
Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in total adverse events compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in total adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
Pegloticase every two weeks (biweekly) showed no clear difference in total adverse events compared with placebo (moderate certainty).
It is very uncertain whether cyclosporin changes adverse events: ESKD compared with placebo or no treatment (very low certainty).
It is very uncertain whether SSRIs or SNRIs changes withdrawn (due to adverse events) compared with placebo (very low certainty).
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: death compared with oral steroids alone (low certainty).
Berotralstat showed no clear difference in adverse events(during compared with placebo or active control (moderate certainty).
Plasma‐derived C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
Recombinant human C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
Lanadelumab showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
Oral hydroxychloroquine showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
Oral dehydroepiandrosterone probably leads to higher adverse events: minor compared with placebo (moderate certainty).